Key facts
- This page summarizes Ely Benaim's Form 4 filing for NovoCure Ltd (NVCR).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 04 Aug 2022, 16:32.
Ely Benaim - 03 Aug 2022 Form 4 Insider Report for NovoCure Ltd (NVCR)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- NVCR
- Reported as of
- 03 Aug 2022
- Net transaction value
- -$439,328
- SEC form
- 4
- Accepted by SEC
- 04 Aug 2022, 16:32:39 UTC
- Prior SEC filing
- 03 Aug 2022
- Next SEC filing
- 10 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Steven Robbins Attorney in Fact for Ely Benaim
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ely Benaim filed Form 4 for NovoCure Ltd (NVCR) on 04 Aug 2022.
Change
- Previous filing in this sequence was filed on 03 Aug 2022.
- Current net transaction value: -$439,328.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NVCR
transaction
Ordinary Shares
Sale
- Transaction value
- $40,024
- Shares
- -563
- Change %
- -1.6%
- Price
- $71.09
- Shares after
- 34,068
- Date
- 03 Aug 2022
- Ownership
- Direct
- Footnotes
- F1
NVCR
transaction
Ordinary Shares
Sale
- Transaction value
- $399,304
- Shares
- -5,396
- Change %
- -16%
- Price
- $74.00
- Shares after
- 28,672
- Date
- 03 Aug 2022
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim.